Tocilizumab versus the Covid19 tempest: All’s well that ends well or much ado about nothing?

oberhuber versus marsh: much ado about nothing?

.

Oberhuber versus Marsh: much ado about nothing?

This issue of the journal features a spirited debate between Oberhuber and Marsh et al regarding the existence and significance of Oberhuber’s sub-classification of the Marsh III lesion into III a, b, c categories. The controversy stems from an article by Marsh and colleagues in an earlier issue of this journal where they present scanning electron microscopic (SEM) images from two cases classif...

Much ado about nothing?

I t all started with the submission of an unsolicited review on idiopathic pulmonary haemosiderosis by IOACHIMESCU et al. [1]. During the review process of this excellent manuscript, the idea evolved to launch a whole series on rare (orphan) interstitial lung disorders in the European Respiratory Journal. Why bother? Well, admittedly, these diseases are rare, but for the affected patient that d...

Much ado about nothing?

Much ado about nothing.